68.87USD+0.81%Mkt Cap: 8.16B USDP/E: 24.15Last update: 2026-05-26
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap8.16B USD
Enterprise Value9.99B USD
Revenue (TTM)1.51B USD
Gross Profit1.17B USD
Net Income (TTM)316.89M USD
Revenue/Share12.72 USD
Last Price68.87 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees423
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS40637H1095
Valuation
P/E (Trailing)24.15
P/E (Forward)6.93
PEG—
EV/EBITDA10.48
EV/Revenue6.62
P/S5.39
P/B36.98
EPS (TTM)2.85
EPS (Forward)9.89
52W Range
51.0657% of range82.22
52W High82.22 USD
52W Low51.06 USD
Profitability
Gross Margin83.62%
Oper. Margin48.98%
EBITDA Margin63.18%
Profit Margin22.69%
ROE649.18%
ROA12.55%
Growth
Revenue Growth42.20%
Earnings Growth31.20%
Cash Flow & Leverage
Operating CF651.56M USD
CapEx (TTM)294.74M USD
FCF Margin15.12%
FCF Yield2.79%
Net Debt1.86B USD
Net Debt/EBITDA1.95
Balance Sheet
Debt/Equity43.89
Current Ratio2.76
Quick Ratio2.14
Book Value/Sh1.853 USD
Cash/Share2.686 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.2 (Buy)
Target (Mean)83.90 USD
Target Range57.00 USD – 96.00 USD
# Analysts10
Ownership
Shares Out.118.61M
Float117.28M
Insiders1.06%
Institutions107.63%
Short Interest
Short Ratio10.3d
Short % Float15.71%
Short % Out.12.14%
Shares Short14.38M
Short (prev mo.)14.05M
Technical
SMA 5065.66 (+4.9%)
SMA 20069.09 (-0.3%)
Beta0.88
S&P 52W Chg28.31%
Avg Vol (30d)1.64M
Avg Vol (10d)2.32M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—